vs
Side-by-side financial comparison of NexPoint Real Estate Finance, Inc. (NREF) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $11.1M, roughly 1.8× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -20.4%, a 237.0% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -48.8%).
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
NREF vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $20.4M |
| Net Profit | $24.0M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 216.6% | -20.4% |
| Revenue YoY | -48.8% | 6.9% |
| Net Profit YoY | 58.7% | 64.9% |
| EPS (diluted) | $0.47 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $20.4M | ||
| Q3 25 | $12.5M | $19.9M | ||
| Q2 25 | $12.1M | $19.6M | ||
| Q1 25 | $11.5M | $17.5M | ||
| Q4 24 | $21.7M | $19.1M | ||
| Q3 24 | $12.5M | $20.2M | ||
| Q2 24 | $6.7M | $21.4M | ||
| Q1 24 | $-12.8M | $19.3M |
| Q4 25 | $24.0M | $-4.2M | ||
| Q3 25 | $50.9M | $-8.2M | ||
| Q2 25 | $22.3M | $-11.9M | ||
| Q1 25 | $26.0M | $-14.2M | ||
| Q4 24 | $15.2M | $-11.8M | ||
| Q3 24 | $23.3M | $-11.1M | ||
| Q2 24 | $12.1M | $-12.3M | ||
| Q1 24 | $-14.6M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | — | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | — | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | — | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | — | -59.2% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | 216.6% | -20.4% | ||
| Q3 25 | 407.0% | -41.0% | ||
| Q2 25 | 184.5% | -61.0% | ||
| Q1 25 | 225.6% | -80.8% | ||
| Q4 24 | 69.9% | -62.1% | ||
| Q3 24 | 186.4% | -54.9% | ||
| Q2 24 | 179.7% | -57.7% | ||
| Q1 24 | 114.3% | -84.4% |
| Q4 25 | $0.47 | $-0.07 | ||
| Q3 25 | $1.14 | $-0.16 | ||
| Q2 25 | $0.54 | $-0.23 | ||
| Q1 25 | $0.70 | $-0.28 | ||
| Q4 24 | $0.71 | $-0.23 | ||
| Q3 24 | $0.74 | $-0.22 | ||
| Q2 24 | $0.40 | $-0.25 | ||
| Q1 24 | $-0.83 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.1M | $92.0M |
| Total DebtLower is stronger | $771.2M | $42.4M |
| Stockholders' EquityBook value | $388.0M | $63.9M |
| Total Assets | $5.3B | $115.3M |
| Debt / EquityLower = less leverage | 1.99× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | $92.0M | ||
| Q3 25 | $17.9M | $92.4M | ||
| Q2 25 | $9.1M | $101.5M | ||
| Q1 25 | $19.2M | $108.8M | ||
| Q4 24 | $3.9M | $120.4M | ||
| Q3 24 | $34.7M | $118.6M | ||
| Q2 24 | $4.3M | $118.2M | ||
| Q1 24 | $13.5M | $127.3M |
| Q4 25 | $771.2M | $42.4M | ||
| Q3 25 | $720.9M | $42.4M | ||
| Q2 25 | $815.6M | $42.4M | ||
| Q1 25 | $831.5M | $42.4M | ||
| Q4 24 | $799.3M | $40.0M | ||
| Q3 24 | $815.5M | $37.1M | ||
| Q2 24 | $861.0M | $35.0M | ||
| Q1 24 | $843.3M | $35.0M |
| Q4 25 | $388.0M | $63.9M | ||
| Q3 25 | $375.4M | $64.3M | ||
| Q2 25 | $348.2M | $70.0M | ||
| Q1 25 | $343.7M | $77.6M | ||
| Q4 24 | $336.5M | $87.5M | ||
| Q3 24 | $335.8M | $95.0M | ||
| Q2 24 | $327.5M | $101.6M | ||
| Q1 24 | $327.1M | $109.2M |
| Q4 25 | $5.3B | $115.3M | ||
| Q3 25 | $5.3B | $116.3M | ||
| Q2 25 | $5.4B | $122.0M | ||
| Q1 25 | $5.4B | $129.7M | ||
| Q4 24 | $5.4B | $142.8M | ||
| Q3 24 | $5.7B | $143.6M | ||
| Q2 24 | $6.6B | $149.7M | ||
| Q1 24 | $7.1B | $155.6M |
| Q4 25 | 1.99× | 0.66× | ||
| Q3 25 | 1.92× | 0.66× | ||
| Q2 25 | 2.34× | 0.61× | ||
| Q1 25 | 2.42× | 0.55× | ||
| Q4 24 | 2.38× | 0.46× | ||
| Q3 24 | 2.43× | 0.39× | ||
| Q2 24 | 2.63× | 0.34× | ||
| Q1 24 | 2.58× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.5M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | -0.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.5M | $-1.8M | ||
| Q3 25 | $8.1M | $-8.7M | ||
| Q2 25 | $3.3M | $-7.5M | ||
| Q1 25 | $16.0M | $-11.6M | ||
| Q4 24 | $4.4M | $-3.5M | ||
| Q3 24 | $14.7M | $362.0K | ||
| Q2 24 | $-7.5M | $-9.5M | ||
| Q1 24 | $17.7M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | -0.19× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | -0.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NREF
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
